TriSalus Life Sciences, Inc. (TLSI)
$4.84-$0.10 (-2.03%) Today
Mary T. Szela - OfficerTriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
https://www.trisaluslifesci.comSEC filings for TLSI on EDGAR
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 4 | 184,551 | |
| Tax withholding / forfeiture | 1 | 14,650 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
46 Form 4 filings on record, the earliest from Nov 15, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| David Patience - Officer | Tax withholding / forfeiture | Common Stock | 14,650 | $4.46 | $65K | |
| Mary T. Szela - Officer | Grant or award | Common Stock | 3,990 | $3.87 | $15K | |
| Richard Marshak - Officer | Grant or award | Common Stock | 561 | $3.87 | $2K | |
| Richard Henry Marshall - Officer | Grant or award | Employee Stock Option (right to buy) | 120,000 | $0.00 | - | |
| Richard Henry Marshall - Officer | Grant or award | Common Stock | 60,000 | $0.00 | - | |
| Richard Marshak - Officer | Open-market sale | Common Stock | 543 | $2.67 | $1K | |
| Mats Wahlstrom - Director | Open-market purchase | Common Stock | 60,000 | $2.53 | $152K | |
| Michael P. Stansky - Director | Open-market purchase | Common Stock | 410,000 | $2.50 | $1.02M | |
| Michael P. Stansky - Director | Open-market purchase | Common Stock | 200,000 | $2.50 | $500K | |
| Mary T. Szela - Officer | Open-market purchase | Common Stock | 39,682 | $2.59 | $103K | |
| David Patience - Officer | Open-market purchase | Common Stock | 7,100 | $2.43 | $17K | |
| Gary B. Gordon - Director | Open-market purchase | Common Stock | 10,000 | $2.46 | $25K | |
| Kerry R. Hicks - Director | Grant or award | Common Stock | 28,201 | $0.00 | - | |
| Kerry R. Hicks - Director | Grant or award | Director Stock Option (right to buy) | 56,403 | $0.00 | - | |
| Mats Wahlstrom - Director | Grant or award | Common Stock | 37,602 | $0.00 | - | |
| Mats Wahlstrom - Director | Grant or award | Common Stock | 34,226 | $0.00 | - | |
| Mats Wahlstrom - Director | Grant or award | Director Stock Option (right to buy) | 75,204 | $0.00 | - | |
| Gary B. Gordon - Director | Grant or award | Common Stock | 28,201 | $0.00 | - | |
| Gary B. Gordon - Director | Grant or award | Common Stock | 24,553 | $0.00 | - | |
| Gary B. Gordon - Director | Grant or award | Director Stock Option (right to buy) | 56,403 | $0.00 | - | |
 David J. Matlin - Director | Grant or award | Common Stock | 28,201 | $0.00 | - | |
| David J. Matlin - Director | Grant or award | Common Stock | 23,065 | $0.00 | - | |
| David J. Matlin - Director | Grant or award | Director Stock Option (right to buy) | 56,403 | $0.00 | - | |
| William Valle - Director | Grant or award | Common Stock | 28,201 | $0.00 | - | |
| William Valle - Director | Grant or award | Common Stock | 24,553 | $0.00 | - | |
| William Valle - Director | Grant or award | Director Stock Option (right to buy) | 56,403 | $0.00 | - | |
| Michael P. Stansky - Director | Grant or award | Common Stock | 23,501 | $0.00 | - | |
| Michael P. Stansky - Director | Grant or award | Common Stock | 20,089 | $0.00 | - | |
| Michael P. Stansky - Director | Grant or award | Director Stock Option (right to buy) | 47,003 | $0.00 | - | |
| Frankenius Equity AB - 10% Owner | Other | Common Stock | 759,000 | $0.00 | - | |
| Frankenius Equity AB - 10% Owner | Other | Series A Convertible Preferred Stock | 230,000 | $0.00 | - | |
| David J. Matlin - Director | Other | Common Stock | 330,000 | $0.00 | - | |
| David J. Matlin - Director | Other | Series A Preferred Stock | 100,000 | $0.00 | - | |
| Jodi Devlin - Officer | Open-market sale | Common Stock | 1,162 | $4.13 | $5K | |
| Jodi Devlin - Officer | Open-market sale | Common Stock | 1,772 | $4.09 | $7K | |
| Jodi Devlin - Officer | Open-market sale | Common Stock | 273 | $4.12 | $1K | |
| Bryan F. Cox - Officer | Open-market sale | Common Stock | 1,138 | $4.13 | $5K | |
| Bryan F. Cox - Officer | Open-market sale | Common Stock | 1,467 | $4.09 | $6K | |
| Bryan F. Cox - Officer | Open-market sale | Common Stock | 579 | $4.12 | $2K | |
| Richard Marshak - Officer | Open-market sale | Common Stock | 1,449 | $4.13 | $6K | |
| Richard Marshak - Officer | Open-market sale | Common Stock | 1,589 | $4.09 | $6K | |
| Richard Marshak - Officer | Open-market sale | Common Stock | 419 | $4.12 | $2K | |
| Jennifer Stevens - Officer | Open-market sale | Common Stock | 1,204 | $4.13 | $5K | |
| Jennifer Stevens - Officer | Open-market sale | Common Stock | 1,552 | $4.09 | $6K | |
| Jennifer Stevens - Officer | Open-market sale | Common Stock | 774 | $4.12 | $3K | |
| Mary T. Szela - Officer | Open-market sale | Common Stock | 4,358 | $4.13 | $18K | |
| Mary T. Szela - Officer | Open-market sale | Common Stock | 15,944 | $3.85 | $61K | |
| David Patience - Officer | Open-market purchase | Common Stock | 3,657 | $4.10 | $15K | |
| Gary B. Gordon - Director | Open-market purchase | Common Stock | 9,756 | $4.10 | $40K | |
| William Valle - Director | Open-market purchase | Common Stock | 30,487 | $4.10 | $125K | |
| Mary T. Szela - Officer | Open-market purchase | Common Stock | 30,487 | $4.10 | $125K | |
| Michael P. Stansky - Director | Open-market purchase | Common Stock | 243,900 | $4.10 | $1.00M | |
| Michael P. Stansky - Director | Open-market purchase | Common Stock | 117,198 | $4.10 | $481K | |
| Michael P. Stansky - Director | Grant or award | Director Stock Option (right to buy) | 92,537 | $0.00 | - | |
| Bryan F. Cox - Officer | Grant or award | Common Stock | 40,000 | $0.00 | - | |
| Bryan F. Cox - Officer | Grant or award | Employee Stock Option (right to buy) | 80,000 | $0.00 | - |
TriSalus Life Sciences, Inc. (TLSI) had 4 insider filings in the last 90 days, with the most recent on 2026-07-06. The full record for TLSI runs to 46 Form 4 filings, the earliest from 2024-11-15. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of TLSI were filed in the last 90 days. 16 purchases are on record for this company.
No insider sales of TLSI were filed in the last 90 days. 17 sales are on record for this company.
This page tracks TLSI Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add TLSI to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
